Get the Stockscreener App
0.00
100.00%
-1.14
After Hours:
1.19
1.19
+
Synlogic Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
See More
Previous Close:
$1.14
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$13.57M
Revenue:
$3.37M
Net Income/Loss:
$-57.28M
P/E Ratio:
0.00
EPS:
-10.7522
Net Cash Flow:
$-51.83M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$1.20
52-Week Range:
$0.00
$1.91
Synlogic Inc Stock (SYBX) Company Profile
Name
Synlogic Inc
Sector
Industry
Phone
617-659-2802
Address
PO BOX 30, WINCHESTER, MA
Compare SYBX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SYBX
Synlogic Inc
|
0.00 | 13.57M | 3.37M | -57.28M | -51.83M | -10.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
498.86 | 126.60B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
590.00 | 64.75B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
639.90 | 36.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.13 | 31.40B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
102.43 | 28.98B | 2.98B | -717.57M | -264.74M | -2.9987 |
Synlogic Inc Stock (SYBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-21-19 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-30-19 | Initiated | Jefferies | Buy |
| Dec-13-18 | Initiated | Chardan Capital Markets | Buy |
| Mar-19-18 | Initiated | H.C. Wainwright | Buy |
| Jan-29-18 | Initiated | Piper Jaffray | Overweight |
View All
Synlogic Inc Stock (SYBX) Latest News
Synlogic’s executive Mary Beth Dooley sells $172 in common stock - Investing.com Australia
Synlogic’s executive Mary Beth Dooley sells $172 in common stock By Investing.com - Investing.com UK
SYBX stock touches 52-week low at $1.14 amid market challenges - Investing.com India
5 Best Microbiome Companies (April 2025) - Securities.io
Gallium Arsenide Market Applications and Semiconductor Industry Impact - openPR.com
Synlogic (NASDAQ:SYBX) Shares Pass Below Fifty Day Moving Average – Here’s Why - Defense World
SYBX stock touches 52-week low at $1.15 amid market challenges - Investing.com Australia
Synlogic (SYBX) to Release Quarterly Earnings on Tuesday - Defense World
Synlogic Inc. (SYBX) reports earnings - Quartz
Week Ahead (Nov.2226): FDA Decision, Data Presentations (ABEO, SYBX, AADI…) - RTTNews
CRISPR and Cas Gene Market May Set a New Epic Growth Story | Fate Therapeutics, Cellectis, Synlogic - Newstrail
Microbiomes Market to Grow by USD 824.3 Million (2025-2029) with Rising Disease Prevalence Boosting the Market, Report on How AI is Redefining Market LandscapeTechnavio - The Malaysian Reserve
Synlogic's executive sells shares worth $2,802 - MSN
Synlogic's executive sells shares worth $2,802 By Investing.com - Investing.com South Africa
Promising Growth Expected in Gout Therapeutics Market, Set to Reach $5.03 Billion by 2029 with a CAGR of 11.7% - WhaTech
Synlogic (SYBX) Stock Price, News & Analysis - MarketBeat
Synlogic announces board member resignation By Investing.com - Investing.com Canada
Synlogic announces board member resignation - Investing.com
The definitive Boston biotech layoff tracker for 2024 - The Business Journals
Fmr LLC Trims Stock Holdings in Synlogic, Inc. (NASDAQ:SYBX) - Defense World
Biopolymers Market to Reach USD 47.4 Billion by 2032 Driven - GlobeNewswire
Synlogic (NASDAQ:SYBX) Trading Down 0.7% – What’s Next? - Defense World
Only the paranoid survive, and the CEO’s paradox, from Aoife Brennan - BioCentury
Urea Cycle Disorder Treatment Market to Grow by USD 215.4 Million (2024-2028), Driven by Rising Prevalence, with AI Redefining Market LandscapeTechnavio - The Malaysian Reserve
Synlogic (FRA:MIN) 3-Year FCF Growth Rate : 21.90% (As of Sep. 2024) - GuruFocus.com
Synlogic (FRA:MIN) Momentum Rank : 2 (As of Nov. 30, 2024) - GuruFocus.com
Phenylketonuria Market size is ~700 USD million in 2023, asserts DelveInsight | Pharma Giants: PTC Therapeutics, Homology Medicines, Synlogic, BioMarin Pharmaceuticals - The Globe and Mail
Microbiomes Market to Grow by USD 1.13 Billion (2024-2028), Rising Disease Prevalence Driving Revenue, with AI Powering Market EvolutionTechnavio - The Malaysian Reserve
Synlogic Third Quarter 2024 Earnings: US$0.01 loss per share (vs US$2.57 loss in 3Q 2023) - Yahoo Finance
Synlogic Reports Q3 2024 Financial Outcomes - TipRanks
Synlogic Reports Third Quarter 2024 Financial Results - GlobeNewswire
Synlogic (SYBX) Slashes Q3 Losses by 99% Amid Strategic Review, No Revenue | SYBX Stock News - StockTitan
The 2024 Biotech Graveyard - Fierce Biotech
Synlogic's head of finance Mary Beth Dooley sells $110 in stock - Investing.com
(PDF) The effects of caffeinated and decaffeinated coffee on sex hormone-binding globulin and endogenous sex hormone levels: A randomized controlled trial - ResearchGate
Oxygen Scavenger Market Set to Reach USD 8.2 Billion by - GlobeNewswire
Synlogic says co entered into sales agreement with Cowen And Company, LLC - Reuters
Urea Cycle Disorders Treatment Market Research In New Report - WhaTech
Synlogic Reports Second Quarter 2024 Financial Results - GlobeNewswire
Otsuka snaps up Jnana with its phenylketonuria drug for $800m - Pharmaceutical Technology
Xilio Therapeutics Appoints Aoife Brennan and James Shannon to its Board of Directors - citybiz
Gut Microbiota Market Set to Reach a Staggering US$ 3,600.1 Million by 2032 - BioSpace
Synlogic Reports First Quarter 2024 Financial Results - GlobeNewswire
Designer Genes: Synlogic Is Crafting Living Therapeutics Programmed to Treat Disease: - Mary Ann Liebert, Inc.
Human Microbiome Market Size & Share to Surpass USD 2,555 million by 2030 - WhaTech
Synlogic Appoints James Flynn to Board Amidst Director Resignations - TipRanks
Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewswire
Synlogic Announces Top Executive Departures and Compensation Deals - TipRanks
Irish-led Synlogic to cease operations after ending drug trial - Silicon Republic
Synlogic Announces Plan to Cease Operations and Reduce Its Workforce by More Than 90% - SynBioBeta
Synlogic reaches end of the road for synthetic biology quest after pivotal data disappoint - Endpoints News
Synlogic Inc Stock (SYBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.89%
1.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):